StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a 52-week low of $0.00 and a 52-week high of $0.00. The firm has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
About Genocea Biosciences
Featured Articles
- Five stocks we like better than Genocea Biosciences
- Short Selling: How to Short a Stock
- 4 Golden Crosses With Double-Digit Upside Ahead
- Earnings Per Share Calculator: How to Calculate EPS
- All-Aboard! Greenbrier Companies Breaks Out, New Highs Ahead
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 High Dividend Socks to Replace Lower Savings Yields Ahead
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.